Michael C Milone - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Michael C Milone

Showing results (101-110 of 106) with videos related to

Pageof 11

Sort By:

You have reached the last page of results.This site can display upto 106 results.

Blood Advances|December 19, 2023

Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokinesGuido Ghilardi, Luca Paruzzo, Jakub Svoboda, et al.

JCI Insight|March 5, 2019

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.

JCI Insight|April 20, 2018

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.

The New England Journal of Medicine|June 3, 2026

Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell TherapyVijay G Bhoj, Mary Kaminski, Huiwu Zhao, et al.

Blood Cancer Discovery|November 22, 2022

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line TherapyAlfred L Garfall, Adam D Cohen, Sandra P Susanibar-Adaniya, et al.

The Journal of Clinical Investigation|June 14, 2016

Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethalityAsim Saha, Roddy S O'Connor, Govindarajan Thangavelu, et al.

Pageof 11

Search research articles

Showing results (101-110 of 106) with videos related to

Sort By:

Pageof 11

You have reached the last page of results.This site can display upto 106 results.

Blood Advances|December 19, 2023

Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokinesGuido Ghilardi, Luca Paruzzo, Jakub Svoboda, et al.

JCI Insight|March 5, 2019

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.

JCI Insight|April 20, 2018

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.

The New England Journal of Medicine|June 3, 2026

Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell TherapyVijay G Bhoj, Mary Kaminski, Huiwu Zhao, et al.

Blood Cancer Discovery|November 22, 2022

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line TherapyAlfred L Garfall, Adam D Cohen, Sandra P Susanibar-Adaniya, et al.

The Journal of Clinical Investigation|June 14, 2016

Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethalityAsim Saha, Roddy S O'Connor, Govindarajan Thangavelu, et al.

Pageof 11